相关实验视频
Updated: Jul 14, 2026

12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
在小鼠中诱导白血病,通过系统地给药肌静止素
Teresa A Zimmers1, Monique V Davies, Leonidas G Koniaris
1Department of Molecular Biology and Genetics, Johns Hopkins School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205, USA.
概括
肌静止素通常会抑制肌肉生长. 在成年小鼠中,肌静素具有系统作用,导致肌肉和脂肪损失,并且可能是治疗肌肉消耗疾病的目标.
科学领域:
- 生物化学 生物化学
- 生理学 生理学 生理学
- 遗传学 是一个遗传学.
背景情况:
- 在肌肉中基因缺陷会导致小鼠和牛骨肌肉质量的增加.
- 肌平素是一种已知抑制肌肉生长的抑制剂.
- 肌肉质量 (产前与产后) 上肌肉的作用时间不清楚.
研究的目的:
- 为了研究成年动物中肌态素的全身作用.
- 为了确定成年小鼠的肌态素活性是否可以调节.
- 探索肌静止素作为肌肉消耗条件的潜在治疗标.
主要方法:
- 在成年小鼠中评估肌静素的循环形式和激活.
- 在成年小鼠中诱导系统性肌静素过度表达.
- 观察肌肉和脂肪质量上肌静止素过度表达的影响.
主要成果:
- 肌态素在成年小鼠中以潜伏形式循环,可通过酸激活.
- 成年小鼠的系统性肌静素过度表达导致显著的肌肉和脂肪损失.
- 观察到的效应模仿了人类缓冲症综合征.
结论:
- 肌静止素在成年动物中具有全身作用.
- 肌平素是肌肉和脂肪质量的关键调节者.
- 肌态是一种潜在的药理学标,用于涉及肌肉损失的疾病,如缓解症.
相关概念视频
Cholinergic Receptors: Muscarinic
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+. Activation...
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+. Activation...
Direct-Acting Cholinergic Agonists: Pharmacological Actions
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Cholinergic Antagonists: Pharmacokinetics
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
Cholinergic Antagonists: Pharmacological Actions
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...

